Chan Heng Fai Ambrose - Dec 13, 2022 Form 4 Insider Report for DSS, INC. (DSS)

Role: Director, 10%+ Owner
Signature: /s/ Heng Fai Ambrose Chan
Stock symbol: DSS
Transactions as of: Dec 13, 2022
Transactions value $: $75,893
Form type: 4
Date filed: 12/14/2022, 07:39 PM
Previous filing: Dec 13, 2022
Next filing: Dec 19, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DSS	Common Stock	Purchase	$75.9K	+335K	+1.8%	$0.23	18.9M	Dec 13, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On December 13, 2022, the reporting person purchased 334,921 shares of the Issuer's common stock. This transaction was executed in multiple trades at prices ranging from $0.1899 to $0.25. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F2	The beneficial ownership of Heng Fai Chan includes a total of 81,786,142 shares of common stock, consisting of (a) 59,552 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 18,914,326 shares of common stock held by Heng Fai Chan directly; (c) 35,213,416 shares of common stock held by Alset Inc.; (d) 21,366,177 shares of common stock held by Alset International Limited, a subsidiary of Alset Inc.; and (e) 6,232,671 shares of common stock held by Global Biomedical Pte. Ltd., a subsidiary of Alset International Limited. Mr. Chan, as indirect beneficial owner, has dispositive control over the securities of the Issuer owned by Alset Inc., Alset International Limited and Global Biomedical Pte. Ltd.

Content

On December 13, 2022, the reporting person purchased 334,921 shares of the Issuer's common stock. This transaction was executed in multiple trades at prices ranging from $0.1899 to $0.25. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

The beneficial ownership of Heng Fai Chan includes a total of 81,786,142 shares of common stock, consisting of (a) 59,552 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 18,914,326 shares of common stock held by Heng Fai Chan directly; (c) 35,213,416 shares of common stock held by Alset Inc.; (d) 21,366,177 shares of common stock held by Alset International Limited, a subsidiary of Alset Inc.; and (e) 6,232,671 shares of common stock held by Global Biomedical Pte. Ltd., a subsidiary of Alset International Limited. Mr. Chan, as indirect beneficial owner, has dispositive control over the securities of the Issuer owned by Alset Inc., Alset International Limited and Global Biomedical Pte. Ltd.